ORIC PHARMACEUTICALS INC (ORIC) Stock Fundamental Analysis

NASDAQ:ORIC • US68622P1093

13.45 USD
-0.05 (-0.37%)
At close: Feb 27, 2026
13.45 USD
0 (0%)
After Hours: 2/27/2026, 8:25:37 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, ORIC scores 3 out of 10 in our fundamental rating. ORIC was compared to 520 industry peers in the Biotechnology industry. While ORIC has a great health rating, there are worries on its profitability. ORIC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ORIC has reported negative net income.
  • In the past year ORIC has reported a negative cash flow from operations.
  • In the past 5 years ORIC always reported negative net income.
  • In the past 5 years ORIC always reported negative operating cash flow.
ORIC Yearly Net Income VS EBIT VS OCF VS FCFORIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • ORIC has a better Return On Assets (-31.37%) than 65.71% of its industry peers.
  • ORIC has a better Return On Equity (-33.24%) than 73.18% of its industry peers.
Industry RankSector Rank
ROA -31.37%
ROE -33.24%
ROIC N/A
ROA(3y)-40.88%
ROA(5y)-34.73%
ROE(3y)-45.86%
ROE(5y)-38.37%
ROIC(3y)N/A
ROIC(5y)N/A
ORIC Yearly ROA, ROE, ROICORIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

  • ORIC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORIC Yearly Profit, Operating, Gross MarginsORIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ORIC has been increased compared to 1 year ago.
  • The number of shares outstanding for ORIC has been increased compared to 5 years ago.
  • There is no outstanding debt for ORIC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ORIC Yearly Shares OutstandingORIC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ORIC Yearly Total Debt VS Total AssetsORIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • ORIC has an Altman-Z score of 29.87. This indicates that ORIC is financially healthy and has little risk of bankruptcy at the moment.
  • ORIC has a Altman-Z score of 29.87. This is amongst the best in the industry. ORIC outperforms 92.15% of its industry peers.
  • There is no outstanding debt for ORIC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.87
ROIC/WACCN/A
WACCN/A
ORIC Yearly LT Debt VS Equity VS FCFORIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 14.65 indicates that ORIC has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 14.65, ORIC belongs to the best of the industry, outperforming 91.38% of the companies in the same industry.
  • ORIC has a Quick Ratio of 14.65. This indicates that ORIC is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 14.65, ORIC belongs to the best of the industry, outperforming 91.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.65
Quick Ratio 14.65
ORIC Yearly Current Assets VS Current LiabilitesORIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 3.89% over the past year.
EPS 1Y (TTM)3.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 3.13% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.68%
EPS Next 2Y5.7%
EPS Next 3Y1.61%
EPS Next 5Y3.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORIC Yearly Revenue VS EstimatesORIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ORIC Yearly EPS VS EstimatesORIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ORIC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ORIC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORIC Price Earnings VS Forward Price EarningsORIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORIC Per share dataORIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.7%
EPS Next 3Y1.61%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ORIC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ORIC PHARMACEUTICALS INC

NASDAQ:ORIC (2/27/2026, 8:25:37 PM)

After market: 13.45 0 (0%)

13.45

-0.05 (-0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-24
Inst Owners102.53%
Inst Owner Change5.87%
Ins Owners1.31%
Ins Owner Change-1.08%
Market Cap1.31B
Revenue(TTM)N/A
Net Income(TTM)-135.27M
Analysts86.67
Price Target21.42 (59.26%)
Short Float %24.85%
Short Ratio14.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.06%
Min EPS beat(2)-4.01%
Max EPS beat(2)20.13%
EPS beat(4)3
Avg EPS beat(4)9.15%
Min EPS beat(4)-4.01%
Max EPS beat(4)20.13%
EPS beat(8)5
Avg EPS beat(8)5.9%
EPS beat(12)9
Avg EPS beat(12)6.37%
EPS beat(16)10
Avg EPS beat(16)4.94%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.03%
EPS NY rev (1m)0%
EPS NY rev (3m)5.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.22
P/tB 3.22
EV/EBITDA N/A
EPS(TTM)-1.73
EYN/A
EPS(NY)-1.61
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0
BVpS4.18
TBVpS4.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.37%
ROE -33.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.88%
ROA(5y)-34.73%
ROE(3y)-45.86%
ROE(5y)-38.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.24%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.65
Quick Ratio 14.65
Altman-Z 29.87
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)134.67%
Cap/Depr(5y)115.51%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
EPS Next Y12.68%
EPS Next 2Y5.7%
EPS Next 3Y1.61%
EPS Next 5Y3.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.05%
EBIT Next 3Y-5.76%
EBIT Next 5YN/A
FCF growth 1Y-50.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.33%
OCF growth 3YN/A
OCF growth 5YN/A

ORIC PHARMACEUTICALS INC / ORIC FAQ

Can you provide the ChartMill fundamental rating for ORIC PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ORIC.


Can you provide the valuation status for ORIC PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ORIC PHARMACEUTICALS INC (ORIC). This can be considered as Overvalued.


How profitable is ORIC PHARMACEUTICALS INC (ORIC) stock?

ORIC PHARMACEUTICALS INC (ORIC) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ORIC stock?

The Earnings per Share (EPS) of ORIC PHARMACEUTICALS INC (ORIC) is expected to grow by 12.68% in the next year.